Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Apriso 0.375G ER CAP
Apriso CAP · 1 trial · 1 indication
Maximum observed plasma concentration levels used for descriptive analysis
| Arm | Type | Description |
|---|---|---|
| Apriso 0.375G ER CAP | EXPERIMENTAL | Apriso 0.375G ER Cap |
| APRISO 375 mg extended-release capsules | ACTIVE_COMPARATOR | APRISO 375 mg ER cap |
| Name | Type | Description |
|---|---|---|
| Apriso 0.375G ER CAP | DRUG | ER capsule |
| APRISO 375 mg extended-release capsules | DRUG | 375 mg extended-release capsules |
Inclusion Criteria: * Healthy male or female, at least 18 years of age * Body mass index (BMI) between18.5 and below 32.0 kg/m2 (inclusive) * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, ECG and labo...
Top 20 of 23 competitors
Apriso CAP is an investigational small molecule developed for ulcerative colitis, a form of inflammatory bowel disease. It is being studied by Bausch Health Companies Inc. under ticker BHC. The program is in Phase 1 clinical development.
Apriso CAP is developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is the sponsor of the clinical program for this ulcerative colitis candidate.
Apriso CAP is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The program has completed one Phase 1 trial with 60 enrolled participants.
Apriso CAP has been studied in one completed Phase 1 trial, NCT03327558. The randomized, double-blind, active-controlled study enrolled 60 healthy male and female subjects in the United States and compared APRISO 375 mg against approved APRISO 375 mg capsules.
Yes, Apriso CAP is also known as Apriso 0.375G ER CAP. Both names refer to the same Bausch Health Companies Inc. product candidate being studied for ulcerative colitis.